ABSTRACT. The majority of autoimmune neuromuscular RATIONALE FOR USE O F IVIG --diseases fall into three groups: 1 ) The autoimmune neuropathies, which include the acute inflammatory demyelinating polyneuropathy (Guillain-Barri. syndrome), the chronic inflammatory demyelinating polyneuropathy, the paraproteinemic polyneuropathies, and the anti-GM1-associated motor neuropathies with conduction block; 2) the inflammatory myopathies, which include the dermatomyositis and polymyositis complex; and 3) the autoimmune neuromuscular junction defects, which include myasthenia gravis, and the Lambert-Eaton myasthenic syndrome. Laboratory and clinical evidence suggests that circulating antibodies or sensitized lymphocytes are operating in the pathogenesis of these conditions. Current immunotherapies include treatment with plasmapheresis, high-dose steroids, or immunosuppressive drugs. Although all of these therapies are effective in a number of patients and for some period of time, they often result in serious side effects that necessitate their discontinuation. The need for safer and more effective therapies in the treatment of these conditions prompted the use of high-dose i.v. immune globulin (IVIG). A number of small trials and a few reports suggest that IVIG is safe and effective in the treatment of patients with autoimmune neuropathies, inflammatory myopathies, and myasthenia gravis unresponsive to conventional therapies. We will present current experience with IVIG in the abovementioned autoimmune neuromuscular diseases, and we will stress the need for long-term controlled studies. The possible immunomodulatory action of IVIG in these conditions will also be discussed. (Pediatr Res 33 (Suppl): S95-S100,1993) Abbreviations IVIG, intravenous immune globulin AChR, acetylcholine receptor CIDP, chronic inflammatory demyelinating polyneuropathy DM, dermatomyositis
Recent advances in the use of high-dose IVIG in a number of autoimmune disorders (1-3) has led to the application of such therapy in neuromuscular diseases. These diseases are of presumed dysimmune or autoimmune pathogenesis and include inflammatory neuropathies, inflammatory myopathies, and autoimmune neuromuscular junction defects. The most accepted treatment for all these disorders, with the exception of GBS, is corticosteroid therapy given in high doses and for long periods of time in an attempt to induce remissions or halt the progression of the disease (4-9). Other immunosuppressive agents, which include azathioprine, cyclophosphamide, cyclosporine, and methotrexate, have also been used, with only limited success, however (6, 9, 10) . The use of these drugs, including steroids, is restricted not only by their limited effectiveness but also by the significant side effects that accompany long-term therapy. PE has also been used in these disorders and is beneficial in GBS (1 1, 12) and MG (7, 10) but is not as helpful in CIDP (13) . Plasmapheresis is ineffective in PM/DM (5) . When PE is used early in the course of GBS, it reduces the time that patients are ventilator-dependent and shortens the time to recovery. Acute exacerbations of myasthenia are also effectively treated with PE, and patients routinely undergo PE around the time of their thymectomies. The use of PE is, however, limited due to technical difficulties such as hemodynamic instability, especially in the elderly with autonomic dysfunction, and poor venous access, particularly in children. The serious side effects from immunosuppressive drugs and the limitations of PE further underscore the need for more effective and safe therapies.
An appraisal of the effectiveness of IVIG in the treatment of these diseases is currently warranted because few studies have been controlled. A review of the treatment trials with IVIG should provide guidelines for the use of this new treatment modality and directions for future research. The actual mode or modes by which IVIG exerts its effect are not clear but do depend on the immunopathogenic mechanism operating in each disease. Identifying how IVIG exerts its effects, particularly its rapid onset of action in certain autoimmune neuromuscular diseases, hinges on understanding the immunopathogenesis of these disorders. They all share similar autoimmune abnormalities, be it circulating antibodies as in MG, altered cellular and humoral immunity as it appears to be in GBS and CIDP, IgG immune complexes or complement-mediated microangiopathy as seen in DM, or a combination of these abnormalities.
MG is probably the prototypic antibody-mediated autoimmune disease to a well-characterized receptor, the acetylcholine nicotinic receptor (AChR). The immunopathogenesis of MG has been reviewed recently (7, 14) and is summarized in (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . The duration of therapy as well as dosing regimens differed between trials, making it difficult to draw definitive conclusions by combining the results of heterogeneous clinical trials. Also, different preparations have been used, which may contain varying amounts of monomeric IgG and F(ab'), fragments. The nature of the preparation may have some ramification as to the efficacy of the drug, particularly as it pertains to the mechanism of action of IVIG in MG. These considerations aside, it appears that about 65% of the treated patients have responded to a single course of high-dose IVIG (14) ( Table 2 ). In the single study that did not show any efficacy (22), six patients were treated with an IVIG dose of 10 g/d for 3 d, a dose much lower than the recommended dosing schedule used by all others. In most studies that reported a response, improvement appeared within 3 wk and may be noted as early as 2 d after the infusion. Duration of the response was variable and seemed to be longer if the patients were receiving concomitant steroids (14). This stresses the possibility that IVIG may have a role as an adjunctive therapy in MG, rather than primary therapy. None of these studies investigated the role of IVIG as a disease course-modifying drug. Certainly, this was not possible, inasmuch as a single dose was used and MG is a condition characterized by fluctuations. Clinical response did not correlate with AChR antibody titer, and only two groups of investigators reported a decline in the titer along with clinical improvement (15-17, 24). In a few case reports, repeated courses were needed to maintain improvement; however, the authors did not comment on any change in the course of the disease.
A number of possible mechanisms have been proposed recently (27, 28) that could explain the mode of action of IVIG. These mechanisms are summarized in Table 3 . The direct effect on antibody-binding site, which would have been suspected in a disease such as MG, has not been demonstrated conclusively, and down-regulation of autoantibody production has been shown in only some patients (15-17, 24). Recent evidence suggests that the primary mode of action of IVIG in antibodymediated autoimmune disorders is through idiotypic-antiidiotypic interactions (1) (2) (3) (27) (28) (29) (30) (31) (32) . This was elegantly demonstrated by Sultan et al. (33) in autoimmune factor VII1:C deficiency. The role of antiidiotypes is not as clear in MG, but experimental evidence indicates that whole IVIG or F(ab'), fragments from IVIG preparations neutralize AChR antibodies in vitro (34) . Furthermore, monoclonal antiidiotypes are therapeutic in EAMG induced by specific AChR epitopes (35). Spontaneously occurring antiidiotypes may have a regulatory role in the pathogenesis of MG (36, 37). Their role in the sera of asymptomatic family members of MG patients is controversial, but one questions how prevalent these antibodies are in the general population (38). Another mechanism proposed for the action of IVIG is Fc receptor blockade. The basis for this proposal is the observation that a beneficial response was obtained from infusions of 7 s but not 5 s IVIG (17, 24).
INFLAMMATORY NEUROPATHIES
A number of recent studies have provided insight into the pathogenesis of inflammatory demyelinating polyneuropathies (6, 8, 9, (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) . The immunopathogenesis of GBS is reviewed by Rostami (this issue). The principal proposed mechanisms are summarized in Tables 4 and 5 . The electrophysiologic principle of weakness in GBS or CIDP, at least early in the disease, is the conduction block produced when a portion of the axon fails to transmit impulses in a segment where myelin has been destroyed or rendered nonfunctional. Antibodies or autoaggressive cytotoxic T cells block myelin components, or saltatory conduction at the nodes of Ranvier may be responsible for this phenomenon. T o understand the immunomodulatory effect of IVIG, one must identify the mechanisms by which myelin is destroyed. More importantly, one has to be able to explain the rapid onset of action of IVIG, which cannot be due to remyelination of demyelinated segments. Rather, there must be one or more factors responsible for conduction failure. The most likely processes are humoral, such as antibodies against myelin, which can lead to complement activation (4 1,43). Autoantibodies to various myelin antigens have been identified in patients with GBS, CIDP, and paraproteinemic neuropathies (41, 47, 49) . Although the exact pathogenic role of these antibodies is not clear, some of the antibodies in GBS fix complement and their titer does correlate with disease activity (41). In the animal model, experimental allergic neuritis, it was shown that complement is deposited in the vicinity of blood vessels and around the myelin at 11 d postinoculation with myelin antigens and before demyelination is observed (45) . The membranolytic attack complex or terminal component of complement (C5b-9) was identified by immunohistochemical methods in the above-mentioned areas, implying a direct role for complement-mediated damage to the nerves (45) . Past studies have also demonstrated deposition of complement components in the nerve biopsies of patients with GBS and CIDP as well as activated components in the sera and spinal fluid of such patients (39, 42-44).
The first case of response to plasma infusion was reported in 198 1, by Maas et al. (50) , in a patient with a relapsing remitting demyelinating polyneuropathy. The patient was treated with varying doses of steroids and azathioprine for 5 y before PE was attempted. Fresh-frozen plasma was administered as replacement fluid, and the patient had a dramatic response within 1 wk of treatment. Another infusion of fresh-frozen plasma, without PE, 3 wk later, resulted in improvement that was similar to that noted after the PE alone. The dramatic response observed after this plasma infusion prompted a trial of high-dose IVIG in a number of patients with CIDP. A review of the literature reveals that, to date, 86 patients with GBS, 101 patients with CIDP, and two patients with paraproteinemic neuropathy have been treated with IVIG (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) . The only truly controlled study was the Dutch GBS trial. One hundred fifty patients were randomized t o receive high-dose IVIG or PE. This study, which was published recently, concluded that IVIG appears to be superior to PE in the treatment of GBS: 52.7% of patients in the IVIG group were improved at 4 wk versus 34.2% of patients in the PE group (67) . In this study, IVIG was not compared to no treatment at all. One interesting finding from the study is that treatment-related fluctuations or early relapses were noted with equal frequency in both IVIG-treated and PE-treated groups (59) . Treatment-related fluctuations have been used previously as an argument to support the autoimmune mechanism of GBS and the efficacy of PE as an immunomodulating agent in this disease. It can be speculated that a similar argument may apply for the role of IVIG. Three of the I 1 patients who had an early relapse and who had received immune globulin responded to another course of high-dose IVIG. Other small series and case reports of patients with GBS also indicate a favorable response to IVIG therapy (58, 60) .
IVIG therapy in CIDP has not been as rigorously investigated. Its eficacy has been reported in approximately 101 patients since 198 1 (50-57, 6 1-66 ), but only one study of seven patients was partially controlled (56) . It is difficult to draw conclusions on the efficacy of IVIG based on these reports because of I ) lack of control data, 2) heterogeneity of the patients studied regarding degree of conduction block, concomitant axonal loss, or other associated illness, and 3) lack of consensus on how CIDP is best defined. With these limitations in mind, it appears that up to 70% of patients improve. Benefit is usually noticeable within the first week and occasionally within hours after beginning the infusion and may last up to 6 wk. In one retrospective analysis of 53 patients, 40% of those who had a favorable response to IVIG required repeat infusions to maintain improvement (54) . The authors of this report felt that if patients had disease of less than I-y duration with ongoing progression and significant demyelination by electrophysiology there was a 93% probability of improvement with IVIG. Whether these criteria will hold true in larger controlled studies remains to be seen. One other study reported a placebo-controlled, crossover treatment trial of seven patients with CIDP that had previously responded to IVIG. These patients were randomized to receive high-dose IVIG or placebo. The results indicate a beneficial effect of IVIG in all of these patients; however, the sample was already preselected and thus biased the study (56) . Clinical response was accompanied by electrophysiologic improvement in a number of patients, but electrical studies were not uniformly required to define benefit (55, 57) . A double-blind, randomized, placebo-controlled study is now ongoing at the NIH.
The paraproteinemic polyneuropathies specifically have not been studied systematically, but some of the reports discussed above included patients with CIDP who had associated gammopathies. We reported on two patients who have been treated since 1988. Both patients responded to high-dose IVIG; one improved 3 wk after the first course and the other after the second monthly infusion. Both have continued to benefit from IVIG and continue to receive monthly infusions. A double-blind study is now ongoing at the NIH for paraproteinemic polyneuropathies.
The proposed immunomodulating properties of IVIG responsible for the beneficial effect in demyelinating neuropathies are as diverse as in any other autoimmune disease (68, 69) . Recently, VanDoorn and colleagues (70, 7 1) reported that whole IVIG or F(ab'h fragments neutralize antibodies to the neuroblastoma cell line detected in patients with CIDP, implying an idiotypelantiidiotype interaction. These antibodies are reportedly present in 42% of patients with GBS and CIDP, but not in healthy adults or in patients with other neurologic diseases (47) . Their significance in the pathogenesis of CIDP and GBS or their role as markers of disease activity remains unknown. Of interest, however, was the observation that postrecovery sera from patients with GBS neutralized the anti-neuroblastoma cell line activity in the prerecovery sera of other GBS and CIDP patients (70, 7 1). This implies that spontaneously occuning antiidiotypes may exist in patients with GBS and may even have a protective role in the natural progression of the disease. The observation that postrecovery-sera antiidiotypes from GBS patients cross-reacted with antibodies from CIDP patients may provide some insight into the source of the antiidiotypes present in IVIG. One can envision that such protective antibodies may be naturally prevalent in subclinical cases of GBS. Other anti-peripheral nerve antibodies have also been detected in patients with inflammatory neuropathies and include anti-GMl, anti-myelin-associated glycoprotein, and antiglucolipids (49) . Healthy adults also have low titers of such anti-peripheral nerve antibodies, which may be the stimulus for the cross-reactive antiidiotypes responsible for the efficacy of IVIG (49, 72) . Another explanation is the solubilization of immune complexes by the IVIG or the competition with complement-binding, anti-peripheral nerve antibodies.
INFLAMMATORY MYOPATHIES
Inflammatory myopathies can be differentiated based on clinical and histologic criteria (73) . Whereas DM is well defined SOUEIDAN A .ND DALAKAS clinically by the typical rash and pattern of weakness, PM is more heterogeneous and essentially is a diagnosis of exclusion requiring the need to search for drug systema, toxic, metabolic, autoimmune, or familial neuromuscular disorders that may mimic its presentation. Both diseases may be suspected in individuals who are genetically predisposed to develop such an autoimmune disease. The pathogenesis of these disorders was recently reviewed (73) and is summarized in Tables 6 through 8. Humoral and cell-mediated immunopathogenic mechanisms are operating in both DM and PM. DM is primarily a humorally mediated microangiopathy that leads to muscle ischemia or infarcts. Deposition of the membranolytic attack complex C5b-9, presumably by antibodies bound to microvascular components, appears to be the earliest lesion preceding inflammation and deposited in the areas of the muscle that still appear intact (74) . Those same areas are underperfused and probably responsible for the early signs of muscle weakness. It is very likely that these lesions may be amenable to reversal with IVIG therapy and may explain the rapid recovery occasionally reported in DM with such treatment. The endomysial inflammatory cellular infiltrate consists predominantly of CD4+ >CD8+ cells. B cells are also present. In contrast, PM is not due to a microangiopathy but rather to a T-cell-mediated cytoxic process that is MHC restricted (73, (75) (76) (77) (78) . In PM, healthy muscle fibers are surrounded or invaded by cytotoxic CD8+ or gamma-delta T cells (77, 78) . The role of autoantibodies is not clear in either DM and PM because they are nonspecific.
Roifman et al. (79) first reported the use of IVIG in inflammatory myopathies in 1987. In 1991, two reports (80, 81) appeared that showed that IVIG was helpful in PM and DM patients. Both were open-label, uncontrolled studies, and a total of 25 patients were treated. The treatment consisted of monthly infusions of high-dose IVIG for a mean duration of 4 mo in one study (80) and 9 mo in the other (8 1). Overall, including the case reports (80, 82), 92% of patients with DM and 73% of patients with PM have responded to IVIG ( Table 9) . A beneficial response was noted within the first week after treatment in some cases, whereas in others it was not noted until after the second infusion, indicating a potential cumulative effect. One can only speculate on the mechanism of action of IVIG in these two diseases, inasmuch as no studies have been conducted to answer this question. In DM, an early response can certainly be due to solubilization of immune complexes that induce the complement deposition in the microvasculature. A reversal of the earliest ischemic lesion can "rescue" the muscle before infarction ensues. Other mechanisms listed in Table 3 could also explain the longterm benefit noted in these two studies, in which the duration of the response ranged from 1 to 24 mo.
CONCLUSIONS
We provide evidence supporting the conclusion that high-dose IVIG is beneficial in autoimmune-related neuromuscular disorders. With the exception of GBS, however, all of these studies are uncontrolled and preliminary. The mechanism of action of IVIG in these diseases remains largely unexplained. The direct effect on antibody-binding sites, which would be most operative in a disease like MG, has not really been demonstrated, and down-regulation of autoantibody production has been shown in only some patients. The possibility of idiotypic/antiidiotypic interaction is an attractive explanation for the beneficial effect in patients with MG, CIDP, and GBS.
The current role of IVIG as the first line therapy or adjunct therapy as a steroid-sparing agent in all of these conditions remains to be defined. Clearly, in GBS the evidence is overwhelming that IVIG compares favorably with PE. In the pediatric age group, in which PE may be impractical, IVIG should be the drug of choice in treating GBS and it should be considered in treating CIDP and MG. IVIG may prove to have a greater role as an adjunctive therapy to other immunosuppressive drugs, especially during exacerbations such as those seen with MG and CIDP. In PM and DM, IVIG appears also to be effective; however, only a double-blind, placebo-controlled trial, such as the one being conducted currently at the NIH, will provide the definitive answer. HIV-infected subjects represent another group of patients who suffer from autoimmune neuromuscular diseases and who may benefit from IVIG therapy. Dr. Schwartz: Do you have any perception as to whether it is necessary to have the high-dosage regimen for efficacy, or would some of the lower-dosage regimens be suitable in terms of this whole spectrum of autoimmune neuropathies? Have you gleaned anything that suggests a trend or is there any evidence for one or the other? Dr. Soueidan: From reviewing the subject and from our limited clinical experience, I feel that the high-dose IVIG is the one that is effective. Whether that is given over a 2-d course as we give it or over a 4-or 5-d course I do not think makes a difference.
Dr. Schwartz: How about duration of effect? Dr. Soueidan: The two paraproteinemic patients have been given infusions every 3 to 4 wk, and that is how we have been managing the patients in our study. That seems to be the experience of most people. We treated one of the patients with weekly infusions of a quarter of the dose, but that did not seem to be as effective as a high-dose infusion given once a month.
Dr. Schwartz: Have you had anyone or been aware of anyone in whom there has been a "cure" and no need for further treatment?
Dr. Soueidan: I am not aware of such patients. That may be an important issue to study, and this is why I feel that IVIG may be an adjunctive treatment, at least in dosage order.
Dr. Levinson: Is any thought being given to trials using a combined approach with IVIG and plasmapheresis? That approach might be particularly useful in a disease like MG, which we know is mediated by autoantibodies. You have talked about the interesting possibilities of antiidiotypic antibodies being involved and we know complement is involved, so plasmapheresis might have something to do with the antibodies and IVIG might have some effect on the antibodies, B cells, or complement deposition. Any thought being given to that kind of approach?
Dr. Soueidan: That goes back to one of the questions that was asked by Dr. Schwartz. If IVIG does turn out to have a disease course-modulating effect, then a combination therapy might seem logical. At the present time that type of therapy is not available. I know Dr. Van Doorn had treated one of his patients with both PE and IVIG and showed that that patient did well. Now whether that patient did better than on IVIG alone or on PE alone, he did not elaborate.
